Road Ahead Unclear For Polyphor’s Intravenous Murepavadin
The Swiss firm is still examining options for the iv formulation of its novel antibiotic murepavadin even after it closed its two Phase III studies on safety concerns.
You may also be interested in...
Spexis is hoping to get ColiFin, a therapy for chronic lung infections in cystic fibrosis patients, onto the US market but cannot start the necessary late-stage program without an injection of cash.
Just over three years, Polyphor's initial public offering in Switzerland raised CHF165m. Now, with just enough cash to get through the third quarter, it has been saved by a deal with US biotech EnBiotix.
Polyphor has seen its remaining asset balixafortide bite the dust and "a strategic assessment regarding the future of the company" is underway for a firm that not so long ago was seen as a rising star in the Swiss biotech sector.